Literature DB >> 21451505

Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.

R M Franke1, C S Lancaster, C J Peer, A A Gibson, A M Kosloske, S J Orwick, R H Mathijssen, W D Figg, S D Baker, A Sparreboom.   

Abstract

The macrolide antiobiotic erythromycin undergoes extensive hepatic metabolism and is commonly used as a probe for cytochrome P450 (CYP) 3A4 activity. By means of a transporter screen, erythromycin was identified as a substrate for the transporter ABCC2 (MRP2) and its murine ortholog, Abcc2. Because these proteins are highly expressed on the biliary surface of hepatocytes, we hypothesized that impaired Abcc2 function may influence the rate of hepatobiliary excretion and thereby enhance erythromycin metabolism. Using Abcc2 knockout mice, we found that Abcc2 deficiency was associated with a significant increase in erythromycin metabolism, whereas murine Cyp3a protein expression and microsomal Cyp3a activity were not affected. Next, in a cohort of 108 human subjects, we observed that homozygosity for a common reduced-function variant in ABCC2 (rs717620) was also linked to an increase in erythromycin metabolism but was not correlated with the clearance of midazolam. These results suggest that impaired ABCC2 function can alter erythromycin metabolism, independent of changes in CYP3A4 activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21451505      PMCID: PMC4519823          DOI: 10.1038/clpt.2011.25

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  43 in total

1.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Mdr1 limits CYP3A metabolism in vivo.

Authors:  L B Lan; J T Dalton; E G Schuetz
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

Review 3.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.

Authors:  J König; A T Nies; Y Cui; I Leier; D Keppler
Journal:  Biochim Biophys Acta       Date:  1999-12-06

4.  Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex.

Authors:  S Haenisch; U Zimmermann; E Dazert; C J Wruck; P Dazert; W Siegmund; S Siegmund; H K Kroemer; R W Warzok; I Cascorbi
Journal:  Pharmacogenomics J       Date:  2006-06-20       Impact factor: 3.550

5.  Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.

Authors:  H C Rawden; D J Carlile; A Tindall; D Hallifax; A Galetin; K Ito; J B Houston
Journal:  Xenobiotica       Date:  2005-06       Impact factor: 1.908

6.  In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay.

Authors:  Justine L Lam; Hideaki Okochi; Yong Huang; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2006-05-12       Impact factor: 3.922

7.  Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

Authors:  Ron H J Mathijssen; Floris A de Jong; Ron H N van Schaik; Erin R Lepper; Lena E Friberg; Trinet Rietveld; Peter de Bruijn; Wilfried J Graveland; William D Figg; Jaap Verweij; Alex Sparreboom
Journal:  J Natl Cancer Inst       Date:  2004-11-03       Impact factor: 13.506

Review 8.  Pharmacogenetics of drug transporters.

Authors:  R M Franke; E R Gardner; A Sparreboom
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

9.  Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Authors:  Federico Innocenti; Deanna L Kroetz; Erin Schuetz; M Eileen Dolan; Jacqueline Ramírez; Mary Relling; Peixian Chen; Soma Das; Gary L Rosner; Mark J Ratain
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

10.  Pharmacogenetic pathway analysis of docetaxel elimination.

Authors:  S D Baker; J Verweij; G A Cusatis; R H van Schaik; S Marsh; S J Orwick; R M Franke; S Hu; E G Schuetz; V Lamba; W A Messersmith; A C Wolff; M A Carducci; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2008-05-28       Impact factor: 6.875

View more
  19 in total

1.  Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.

Authors:  Anand K Deo; Bhagwat Prasad; Larissa Balogh; Yurong Lai; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2012-02-08       Impact factor: 3.922

2.  Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.

Authors:  J A Sprowl; V Gregorc; C Lazzari; R H Mathijssen; W J Loos; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

3.  PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.

Authors:  Alison E Fohner; Alex Sparreboom; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-04       Impact factor: 2.089

Review 4.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 5.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.

Authors:  Kazuhiro Yamamoto; Ikuko Yano
Journal:  Med Oncol       Date:  2018-01-04       Impact factor: 3.064

Review 7.  Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation.

Authors:  Camille Tron; Florian Lemaitre; Céline Verstuyft; Antoine Petitcollin; Marie-Clémence Verdier; Eric Bellissant
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

8.  Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.

Authors:  Vera Kim; Thijs van der Wal; Miriam Yumie Nishi; Luciana Ribeiro Montenegro; Flair Jose Carrilho; Yujin Hoshida; Suzane Kioko Ono
Journal:  Pharmacogenomics       Date:  2020-06-03       Impact factor: 2.533

9.  OATP1B1 polymorphism as a determinant of erythromycin disposition.

Authors:  C S Lancaster; G H Bruun; C J Peer; T S Mikkelsen; T J Corydon; A A Gibson; S Hu; S J Orwick; R H J Mathijssen; W D Figg; S D Baker; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2012-09-19       Impact factor: 6.875

Review 10.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.